日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Intestinal human carboxylesterase 2 (CES2) expression rescues drug metabolism and most metabolic syndrome phenotypes in global Ces2 cluster knockout mice

肠道人类羧酸酯酶 2 (CES2) 表达挽救了整体 Ces2 簇敲除小鼠的药物代谢和大多数代谢综合征表型

Yao-Geng Wang, Chang-Pei Gan, Joke Beukers-Korver, Hilde Rosing, Wen-Long Li, Els Wagenaar, Maria C Lebre, Ji-Ying Song, Colin Pritchard, Rahmen Bin Ali, Ivo Huijbers, Jos H Beijnen, Alfred H Schinkel

Interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugs

OATP1A/1B/2B1 摄取转运体与 ABCB1 和 ABCG2 外排转运体在胆红素和药物处理中的相互作用

Wenlong Li, Rolf W Sparidans, Yaogeng Wang, Margarida L F Martins, Dirk R de Waart, Olaf van Tellingen, Ji-Ying Song, Maria C Lebre, Stéphanie van Hoppe, Els Wagenaar, Jos H Beijnen, Alfred H Schinkel

Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism

羧酸酯酶 1 家族敲除改变药物分布和脂质代谢

Changpei Gan, Jing Wang, Alejandra Martínez-Chávez, Michel Hillebrand, Niels de Vries, Joke Beukers, Els Wagenaar, Yaogeng Wang, Maria C Lebre, Hilde Rosing, Sjoerd Klarenbeek, Rahmen Bin Ali, Colin Pritchard, Ivo Huijbers, Jos H Beijnen, Alfred H Schinkel

ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability

ABCB1 限制了 KRASG12C 抑制剂 sotorasib 在脑内的暴露,而 ABCB1、CYP3A 以及可能的 OATP1a/1b 则限制了其口服有效性

Nancy H C Loos, Irene A Retmana, Wenlong Li, Margarida L F Martins, Maria C Lebre, Rolf W Sparidans, Jos H Beijnen, Alfred H Schinkel

Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis

阿达木单抗治疗对轻度银屑病关节炎患者皮肤和滑膜中白细胞介素 17 和白细胞介素 17 受体表达的影响

Janne W Bolt, Arno W van Kuijk, Marcel B M Teunissen, Dennis van der Coelen, Saïda Aarrass, Daniëlle M Gerlag, Paul P Tak, Marleen G van de Sande, Maria C Lebre, Lisa G M van Baarsen

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure

P-糖蛋白 (MDR1/ABCB1) 限制新型 EGFR 抑制剂 EAI045 在脑内的蓄积,同时口服 Elacridar 可增强其在脑内的蓄积和口服暴露

Jing Wang, M Merve Susam, Changpei Gan, Rolf W Sparidans, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel

ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability

ABCB1 和 ABCG2 控制新型 ROS1/TRK/ALK 抑制剂 Repotrectinib 在脑内的蓄积和肠道分布,而 OATP1A/1B、ABCG2 和 CYP3A 限制其口服可用性

Wenlong Li, Rolf W Sparidans, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel

P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib

P-糖蛋白 (ABCB1/MDR1) 控制 PARP1/2 抑制剂尼拉帕尼的脑渗透和肠道分布

Margarida L F Martins, Nancy H C Loos, Sümeyra Mucuk, Danielle de Jong, Maria C Lebre, Hilde Rosing, Matthijs Tibben, Jos H Beijnen, Alfred H Schinkel

P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)

P-糖蛋白 (ABCB1/MDR1) 和 BCRP (ABCG2) 限制脑内蓄积,细胞色素 P450-3A (CYP3A) 限制 RET 抑制剂 Selpercatinib (RETEVMO) 的口服暴露

Yaogeng Wang, Rolf W Sparidans, Sander Potters, Rahime Şentürk, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel

Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammation

抗 TNF 疗法可降低类风湿关节炎患者血清中的趋化因子水平:抗 TNF 可能减轻炎症的新机制

Marieke M J Herenius, Ana S F Oliveira, Carla A Wijbrandts, Daniëlle M Gerlag, Paul P Tak, Maria C Lebre